| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Thrombosis |
1 Gruppo di Studio sull’Immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo;
2 Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrologiche, Università di Palermo;
3 Istituto Nazionale di Riposo e Cura per Anziani, Ancona, and Dipartimento di Patologia Sperimentale, Università di Bologna, Bologna, Italy
Correspondence: Giuseppina Candore, PhD, Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, corso Tukory 211, 90134 Palermo, Italy. Phone: international +39.091.6555911. Fax: international +39.091.6555933., E-mail:gcandore{at}unipa.it orcrbalistreri{at}unipa.it
Key words: atherosclerosis, AMI, CCR5, CCR5
32, inflammation, longevity.
Inflammation is involved in the pathophysiology of atherosclerosis and its clinical complications, such as AMI. Several pro-inflammatory molecules have been identified in atherosclerotic lesions. Chemokines and their receptors seem to play a pivotal role in the genesis and progression of atherosclerosis.1 CCR5 is a β-chemokines receptor involved in the migration of monocytes, NK cells and some T cells to the inflammation site. Recent evidence has suggested its involvement in human diseases, such as infectious and age-related inflammatory diseases including atherosclerosis.2,3 A possible association between CCR5 gene (NM-U83326) variants and AMI has, therefore, been suggested. Accordingly, CCR532 variant, a non functional allele resulting from a 32-bp deletion in exon 4 (rs333), seems to have a protective role against AMI and coronary heart diseases (CHD), determining a slower progression of atherosclerotic lesion as a consequence of an attenuated inflammatory response. However, conflicting results have been obtained regarding the CCR5 role in atherosclerosis.3–5 In this study, we evaluated whether CCR532 variant and two other functional single nucleotide polymorphisms (SNPs) in CCR5 gene promoter6,7 might be associated with AMI. We also analyzed their distribution in centenarians, since our previous studies have demonstrated that alleles associated with AMI susceptibility are not included in the genetic background favoring longevity.8 We enrolled 133 young subjects (<45 years) selected among AMI patients admitted to the Intensive Coronary Therapy Unit of Palermo University Hospital. Diagnosis was based on identification of electrocardiograph and serum enzyme activity changes confirmed by echocardiography and coronary angiography. All 133 patients suffered from AMI with or without ST-segment elevation. However, accurate information about the number of occluded arteries was not available. They were consecutively enrolled during the last three years immediately before they were discharged, i.e. 4–10 days after AMI occurrence. In this sample of patients, no mortality was observed during the hospital admission. Smokers accounted for 74% of patients, there was family CVD history in 52.6%, type 2 diabetes in 18%, obesity in 34%, hypertension in 29%, hypercholesterolemia in 61%, and hypertriglyceridemia in 43%. A matched control group consisted of 136 subjects in good health according to their clinical history and blood tests (complete blood cell count, erythrocyte sedimentation rate, glucose, urea nitrogen, creatinine, electrolytes, C reactive protein, liver function tests, iron, proteins, cholesterol, triglycerides). Among young controls, 21.3% were moderate smokers; no other cardiac risk factor was present. A second control group consisted of 123 Sicilian centenarians (> 99 years), whose age was confirmed from records at the City Hall and/or Church registries. No cardiac risk factors or age-related diseases were observed in centenarians, although some had reduced auditory and visual acuity (as expected9 most biochemical parameters including cholesterol and triglycerides, were in the normal range). Because immigration and intermarriage have historically been rare, Sicilian ethnicity of all participants was established by all four grandparents having been born in Sicily.
The study was approved by the University Hospital Ethics Committee, and written informed consent was obtained from all participants. DNA was genotyped for CCR532 variant and two SNPs of promoter CCR5 gene region, 59029A/G and 59353C/T, as published.6,7 Differences in allele and genotypic frequencies of three CCR5 variants among three groups were evaluated by gene count and 
2 test. ODD ratio (OR) with confidence interval (CI) was also calculated. Due to the small number of AMI women patients, a logistic regression to test the association of pro-inflammatory wild type CCR5 genotype with AMI taking into account the cardiac risk factors was only carried out in male patients and controls. We found significant differences in frequency of CCR532 genotypes between controls and patients (p=0.005 by 2 test; OR=0.16, 95%CI=0.046–0.56, p=0.003 by Fisher’s exact test). Therefore, there was a significantly higher prevalence of 32 allele in controls than AMI patients (p=0.0007, by 2 test with Yates’ correction; OR=0.14 95%CI=0.04–0.48, p=0.0008 by Fisher’s exact test). By contrast, no statistical differences were observed in the genotype distributions and the allele frequencies of 59029A/G and 59353C/T promoter SNPs between AMI patients and matched controls (Table 1, online supplement).
|
32 deletion in 123 Sicilian centenarians is shown in Table 1. To focus the attention on significant genotypic and allele differences in three cohorts, this table also reports the CCR532 data of two groups previously described. Significant differences were found in genotypic frequency among the three groups (p=0.003 by 2 test). Accordingly, the same results were obtained for CCR532 allele frequency among the three groups (p=0.00006 by 2 test). The CCR532 allele was under-represented in AMI patients and over-represented in centenarians, with intermediate values in age-matched controls. After adjustment for risk factors, significant differences in pro-inflammatory wild type CCR5 allele were observed between male AMI patients and matched controls ( p=0.0003, OR 3.3 (2.5–8.6) and between male AMI patients and centenarians (p=0.00001, OR 7.6 (3.01–9.8)) (Table 1). These results therefore indicate that pro-inflammatory wild-type CCR5 genotype is an independent risk factor for developing AMI in the Sicilian population. Results from our study of a homogeneous population suggest that CCR532 variant is associated with AMI. Association studies are influenced by a number of possible confounding factors, such as, among others, the total number of patients and controls and the homogeneity of the population in terms of geographical origin. False associations might occur if the controls are not ethnically matched with the patients. We compared people belonging to the same homogeneous population from Sicily. Therefore, we think that, although based on a relatively reduced number of patients and controls, our results might more reliable than studies performed on larger cohorts of patients from northern Europe and the United States which are ethnically matched but only refer to Caucasians in general. Genetic traits significantly contribute to the CVD risk and literature data indicate that innate immunity alleles may increase the risk of disease. Accordingly, common gene polymorphisms regulating high inflammatory molecule production have been associated with atherosclerosis. Conversely, those associated with a positive control of inflammation might play a protective role against atherosclerosis. However, contrasting results have been obtained in different populations, including the molecule under study.1,4,5,10,11
Since centenarian offspring seem to have a significant reduction in CVD prevalence,8 we performed centenarian genetic studies to clarify the role of key genetic components influencing AMI. We have demonstrated in previous studies that alleles associated to CHD susceptibility are not included in the genetic background favoring longevity. So, genetic background promoting pro-inflammatory responses may play an opposite role in CVD and longevity.8 In agreement with our hypothesis the results show that the role of CCR532 variant confers AMI resistance and promotes longevity in Sicilians.
In the clean modern Western environment, with reduced pathogen load and improved control of severe infections by vaccinations and antibiotics, the CCR532 anti-inflammatory genotype might result in an increase in longevity, since it reduces the risk of atherosclerosis.10,12
 |
Footnotes |
|---|
|
References |
|---|
 TOP References |
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
